Microbiome and <i>EGFR</i> -mutant non-small cell lung cancer: a complex interplay
Despite its emerging role, microbiome research in <i>EGFR</i>-mutant NSCLC holds substantial potential to refine therapeutic outcomes. Microbiota-targeted interventions may improve TKIs efficacy, mitigate toxicity, and potentially expand immunotherapeutic options in this molecularly and immunologically 'cold' subgroup. Future integrative studies combining microbiome, metabolome, and immune profiling are essential to translate these insights into personalized clinical strategies.
Authors
- Lucia Longo (ORCID: https://orcid.org/0000-0003-4805-6241)
- A. Avancini
- Ilaria Trestini (ORCID: https://orcid.org/0000-0002-4958-9771)
- Adele Bonato
- Ilaria Mariangela Scaglione
- Luca Pasqualin
- Lorenzo Belluomini (ORCID: https://orcid.org/0000-0003-1981-5499)
- Daniela Tregnago
- Michele Rota (ORCID: https://orcid.org/0009-0005-1684-7024)
- Jessica Insolda
- Serena Eccher
- Marco Sposito
- Sara Pilotto
- Michele Milella
Institutions
- University of Verona (IT)
- Ospedale Santa Chiara (IT)
- Federico II University Hospital (IT)
Publication Details
- Journal
- Expert Review of Clinical Immunology
- Published
- 2026-03-13
- DOI
- https://doi.org/10.1080/1744666x.2026.2645844
- Primary Topic
- Gut microbiota and health
- Type
- article
- Field-Weighted Citation Impact
- 0.00